Q-linea (QLINEA) Q1 2026 earnings summary

Executive summary

• Achieved record Q1 for instrument placements and consumables demand, driven by FDA clearance of the expanded ASTar panel, which now offers the broadest antibiotic and pathogen coverage in the US and reinforces leadership in rapid AST for Gram-negative infections.

• Commercial momentum increased in the US, with new contracts and installations, and continued expansion in Europe, Middle East, and Asia, including first DACH region contract and multi-site projects.

• Organizational restructuring completed, reducing OpEx to SEK 10.7 million per month and delivering SEK 16 million in annual cost savings.

• Record month for global consumables shipments in March, with Italy and the GCC as main contributors.

• Planned launch of a dedicated non-blood isolate kit under research use only registration in Q3 2026 to address customer requests and expand market reach.

Financial highlights

• Net sales for Q1 2026 were SEK 2.0 million, down from SEK 3.7 million year-over-year due to lower capital sales, but consumables revenue rose 60% to SEK 1.4 million.

• Operating expenses for Q1 2026 were SEK 32.1 million (SEK 10.7 million/month), a 47% reduction from Q1 2023.

• Operating result (EBIT) improved to SEK -35.0 million from SEK -44.6 million year-over-year.

• Cash and cash equivalents at quarter-end were SEK 223.9 million, with an equity ratio of 91%.

• Cash flow from operating activities improved to SEK -30.2 million from SEK -49.0 million year-over-year.

Outlook and guidance

• US market activity expected to accelerate from Q2 2026 following FDA clearance, with strong visibility for placements in H2 2026.

• Additional cost savings expected from office consolidation and ongoing COGS initiatives, with OpEx targeted below SEK 11 million/month.

• Gross margin expansion anticipated as consumables volumes increase and COGS are reduced.

• Focus on converting US pipeline, expanding into new distribution markets, and increasing test volumes in Italy despite budget constraints.

• Launch of a dedicated non-blood isolate kit planned for Q3 2026.